GARDEN CITY, N.Y., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, will participate in one-on-one meetings and a presentation at the Lytham Partners 2025 Investor Healthcare Summit, taking place virtually on Monday, January 1 ...

The Phase 1b study will evaluate LV UNO in unresectable cutaneous or subcutaneous histologically confirmed primary or metastatic solid tumor cancer patients that have progressed or have prolonged stable disease on single agent PD-1 inhibitors The primary objective of the Phase 1b study is to assess preliminary efficacy by objective response rate (ORR) and duration of response (DOR) per RECIST version 1.1 and secondarily immune-related response via iRECIST The study will recruit patients from four sites acro ...

Indication covers newborn infants with hypoxic respiratory failure and peri- and post-operative pulmonary hypertension to improve right ventricular function in conjunction with heart surgery A $1 million milestone payment is triggered from Asia-Pacific partner, Getz Healthcare GARDEN CITY, N.Y., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) ...

DUBLIN and GARDEN CITY, N.Y., Nov. 26, 2024 (GLOBE NEWSWIRE) -- NeuroNOS, a pioneering biopharmaceutical company focused on developing transformative treatments for Autism Spectrum Disorder (ASD) and other complex neurological conditions, and a subsidiary of Beyond Air (NASDAQ: XAIR), is proud to announce the appointment of Professor Roger D. Kornberg, to its Scientific Advisory Board (SAB). This appointment marks a key milestone in NeuroNOS's commitment to advancing scientific innovation and improving the ...

Exhibit 99.1 Beyond Air® Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update Revenues increased 17% compared to the previous quarter ended June 30, 2024 Strengthened balance sheet is expected to provide suf icient cash runway through June 2026 Completed a $20.6 million private placement of ering with multiple healthcare-focused institutional funds and Company insiders Retired $17.5 million in debt from Avenue Capital and entered into a $11.5 million loan agreement with an insi ...

GARDEN CITY, N.Y., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of Nitric Oxide (NO) to improve the lives of patients, today announced that Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, will participate in one-on-one meetings and a fireside chat at the Piper Sandler 36th Annual Healthcare Conference being held December 3-5, 2024 in New York. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class: Trading Symbol Name of each exchange on which registered: Common Stock, par value $0.0001 per share XAIR The Nasdaq Stock Market LLC FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________to ...

Beyond Air, Inc. (NASDAQ:XAIR) Q2 2025 Earnings Conference Call November 11, 2024 4:30 PM ET Company Participants Corey Davis - Investor Relations, LifeSci Advisors Steve Lisi - Chairman and Chief Executive Officer Douglas Larson - Chief Financial Officer Conference Call Participants Jason Wittes - ROTH MKM Partners Marie Thibault - BTIG Yale Jen - Laidlaw & Company Matt Kaplan - Ladenburg Thalmann Operator Good afternoon, and welcome, everyone to the Beyond Air Financial Results Call for the Fiscal Quarter ...

Beyond Air, Inc. (XAIR) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.51 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 6.67%. A quarter ago, it was expected that this company would post a loss of $0.29 per share when it actually produced a loss of $0.27, delivering a surprise of 6.90%. Over the last four quarters, the company has surpasse ...

Revenues increased 17% compared to the previous quarter ended June 30, 2024 Strengthened balance sheet is expected to provide sufficient cash runway through June 2026 Completed a $20.6 million private placement offering with multiple healthcare-focused institutional funds and Company insiders Retired $17.5 million in debt from Avenue Capital and entered into a $11.5 million loan agreement with an insider-led investor group Conference call scheduled for 4:30 p.m. ET today, November 11th GARDEN CITY, N.Y., No ...